naftidrofuryl 🐶 Veterinary Use | Indications/Contra | FAERs-F | FAERs-M | Orange Bk | BioActivity |
| Stem definition | Drug id | CAS RN |
|---|---|---|
| 1870 | 31329-57-4 |
Description:
| Molecule | Description |
|---|---|
|
Synonyms:
|
A drug used in the management of peripheral and cerebral vascular disorders. It is claimed to enhance cellular oxidative capacity and to be a spasmolytic. (From Martindale, The Extra Pharmacopoeia, 30th ed, p1310) It may also be an antagonist at 5HT-2 serotonin receptors.
|
Drug dosage:
| Dose | Unit | Route |
|---|---|---|
| 0.60 | g | O |
ADMET properties:
| Property | Value | Reference |
|---|---|---|
| Vd (Volume of distribution) | 0.98 L/kg | Lombardo F, Berellini G, Obach RS |
| CL (Clearance) | 10.80 mL/min/kg | Lombardo F, Berellini G, Obach RS |
| fu (Fraction unbound in plasma) | 0.20 % | Lombardo F, Berellini G, Obach RS |
| t_half (Half-life) | 1.35 hours | Lombardo F, Berellini G, Obach RS |
Approvals:
None
FDA Adverse Event Reporting System (Female)
None
FDA Adverse Event Reporting System (Male)
| MedDRA adverse event term | Likelihood ratio | Likelihood ratio threshold | Patients taking drug having adverse event | Patients taking drug not having adverse event | Patients not taking drug having adverse event | Patients not taking drug not having adverse event |
|---|---|---|---|---|---|---|
| Acute kidney injury | 57.29 | 47.71 | 44 | 540 | 304944 | 34651403 |
| Lactic acidosis | 51.69 | 47.71 | 20 | 564 | 34752 | 34921595 |
FDA Adverse Event Reporting System (Geriatric)
| MedDRA adverse event term | Likelihood ratio | Likelihood ratio threshold | Patients taking drug having adverse event | Patients taking drug not having adverse event | Patients not taking drug having adverse event | Patients not taking drug not having adverse event |
|---|---|---|---|---|---|---|
| Acute kidney injury | 82.84 | 39.34 | 59 | 872 | 519345 | 79224112 |
| Lactic acidosis | 54.73 | 39.34 | 23 | 908 | 70336 | 79673121 |
| Hyperkalaemia | 52.85 | 39.34 | 26 | 905 | 114372 | 79629085 |
FDA Adverse Event Reporting System (Pediatric)
None
Pharmacologic Action:
| Source | Code | Description |
|---|---|---|
| ATC | C04AX21 | CARDIOVASCULAR SYSTEM PERIPHERAL VASODILATORS PERIPHERAL VASODILATORS Other peripheral vasodilators |
| MeSH PA | D002317 | Cardiovascular Agents |
| MeSH PA | D018377 | Neurotransmitter Agents |
| MeSH PA | D018490 | Serotonin Agents |
| MeSH PA | D012702 | Serotonin Antagonists |
| MeSH PA | D014665 | Vasodilator Agents |
Drug Use | Suggest Off label Use Form| |View source of the data|
| Disease | Relation | SNOMED_ID | DOID |
|---|---|---|---|
| Cerebrovascular disease | indication | 62914000 | DOID:6713 |
| Chronic Occlusive Peripheral Arterial Disease | indication |
🐶 Veterinary Drug Use
None
🐶 Veterinary products
None
Acid dissociation constants calculated using MoKa v3.0.0
| Dissociation level | Dissociation constant | Type (acidic/basic) |
|---|---|---|
| pKa1 | 8.43 | Basic |
Orange Book patent data (new drug applications)
None
Orange Book exclusivity data (new drug applications)
None
Bioactivity Summary:
| Target | Class | Pharos | UniProt | Action | Type | Activity value (-log[M]) | Mechanism action | Bioact source | MoA source |
|---|---|---|---|---|---|---|---|---|---|
| 5-hydroxytryptamine receptor 2A | GPCR | Ki | 6.82 | CHEMBL |
External reference:
| ID | Source |
|---|---|
| D05107 | KEGG_DRUG |
| 3200-06-4 | SECONDARY_CAS_RN |
| C0027329 | UMLSCUI |
| CHEBI:91817 | CHEBI |
| CHEMBL1439099 | ChEMBL_ID |
| CHEMBL1620794 | ChEMBL_ID |
| CHEMBL1443491 | ChEMBL_ID |
| DB13588 | DRUGBANK_ID |
| 2177 | INN_ID |
| 42H8PQ0NMJ | UNII |
| 4417 | PUBCHEM_CID |
| 7236 | RXNORM |
| 003746 | NDDF |
| 003776 | NDDF |
| 006857 | NDDF |
| 006858 | NDDF |
| 350627007 | SNOMEDCT_US |
| 395807000 | SNOMEDCT_US |
| 395992001 | SNOMEDCT_US |
| D009257 | MESH_DESCRIPTOR_UI |
Pharmaceutical products:
None